Cargando…
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2. Given that liver cirrhosis patients exhibit hyponatremia due to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197450/ https://www.ncbi.nlm.nih.gov/pubmed/34070416 http://dx.doi.org/10.3390/ijms22115582 |
_version_ | 1783706919763968000 |
---|---|
author | Adachi, Takuya Takeuchi, Yasuto Takaki, Akinobu Oyama, Atsushi Wada, Nozomu Onishi, Hideki Shiraha, Hidenori Okada, Hiroyuki |
author_facet | Adachi, Takuya Takeuchi, Yasuto Takaki, Akinobu Oyama, Atsushi Wada, Nozomu Onishi, Hideki Shiraha, Hidenori Okada, Hiroyuki |
author_sort | Adachi, Takuya |
collection | PubMed |
description | Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2. Given that liver cirrhosis patients exhibit hyponatremia due to their pseudo-aldosteronism and usage of natriuretic agents, a sodium maintaining agent, such as tolvaptan, is physiologically preferable. However, large scale studies indicating the patients for whom this would be effective and describing management under its use have been insufficient. The appropriate management of cirrhosis patients treated with tolvaptan should be investigated. In the present review, we collected articles investigating the effectiveness of tolvaptan and factors associated with survival and summarized their management reports. Earlier administration of tolvaptan before increasing the doses of natriuretic agents is recommended because this may preserve effective arterial blood volume. |
format | Online Article Text |
id | pubmed-8197450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81974502021-06-13 Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan Adachi, Takuya Takeuchi, Yasuto Takaki, Akinobu Oyama, Atsushi Wada, Nozomu Onishi, Hideki Shiraha, Hidenori Okada, Hiroyuki Int J Mol Sci Review Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2. Given that liver cirrhosis patients exhibit hyponatremia due to their pseudo-aldosteronism and usage of natriuretic agents, a sodium maintaining agent, such as tolvaptan, is physiologically preferable. However, large scale studies indicating the patients for whom this would be effective and describing management under its use have been insufficient. The appropriate management of cirrhosis patients treated with tolvaptan should be investigated. In the present review, we collected articles investigating the effectiveness of tolvaptan and factors associated with survival and summarized their management reports. Earlier administration of tolvaptan before increasing the doses of natriuretic agents is recommended because this may preserve effective arterial blood volume. MDPI 2021-05-25 /pmc/articles/PMC8197450/ /pubmed/34070416 http://dx.doi.org/10.3390/ijms22115582 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Adachi, Takuya Takeuchi, Yasuto Takaki, Akinobu Oyama, Atsushi Wada, Nozomu Onishi, Hideki Shiraha, Hidenori Okada, Hiroyuki Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan |
title | Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan |
title_full | Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan |
title_fullStr | Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan |
title_full_unstemmed | Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan |
title_short | Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan |
title_sort | management of cirrhotic ascites under the add-on administration of tolvaptan |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197450/ https://www.ncbi.nlm.nih.gov/pubmed/34070416 http://dx.doi.org/10.3390/ijms22115582 |
work_keys_str_mv | AT adachitakuya managementofcirrhoticascitesundertheaddonadministrationoftolvaptan AT takeuchiyasuto managementofcirrhoticascitesundertheaddonadministrationoftolvaptan AT takakiakinobu managementofcirrhoticascitesundertheaddonadministrationoftolvaptan AT oyamaatsushi managementofcirrhoticascitesundertheaddonadministrationoftolvaptan AT wadanozomu managementofcirrhoticascitesundertheaddonadministrationoftolvaptan AT onishihideki managementofcirrhoticascitesundertheaddonadministrationoftolvaptan AT shirahahidenori managementofcirrhoticascitesundertheaddonadministrationoftolvaptan AT okadahiroyuki managementofcirrhoticascitesundertheaddonadministrationoftolvaptan |